Respirion Pharmaceuticals is an early-stage biotechnology company focused on developing new treatments for respiratory diseases.
Respirion Pharmaceuticals has raised $649K in total funding. The most recent round was Grant. The last funding was announced in November 2025.
Respirion Pharmaceuticals's investors include Brandon Capital, Medical Research Future Fund (MRFF), Brandon BioCatalyst, Medical Research Commercialisation Fund (MRCF), Future Health Research and Innovation.
Respirion Pharmaceuticals is headquartered in Perth, Australia.
Respirion Pharmaceuticals is an early-stage biotechnology company focused on developing new treatments for respiratory diseases.
Respirion Pharmaceuticals is at the Grant stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Respirion Pharmaceuticals — Funding & Investors." VCBacked, November 19, 2025, https://www.vcbacked.co/company/respirion-pharmaceuticals. Accessed August 15, 2026.
VCBacked. (2025). Respirion Pharmaceuticals — Funding & Investors. Retrieved August 15, 2026, from https://www.vcbacked.co/company/respirion-pharmaceuticals
{{cite web |title=Respirion Pharmaceuticals — Funding & Investors |url=https://www.vcbacked.co/company/respirion-pharmaceuticals |website=VCBacked |access-date=August 15, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated